Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
Nurix Therapeutics (Nasdaq: NRIX) has appointed Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur brings over 25 years of executive experience in pharmaceutical and biotech companies across U.S. and international markets. His expertise in commercial operations and launching novel drugs in hematology and oncology is particularly relevant to Nurix's pipeline.
Mr. Kapur's notable achievements include launching blockbuster drugs Imbruvica and Darzalex while at Johnson & Johnson. He has held senior leadership positions at various companies, including Geron , Actinium Pharmaceuticals, and Bristol-Myers Squibb. Nurix is preparing to advance NX-5948 into pivotal clinical testing in 2025 and is planning for future commercialization.
Nurix Therapeutics (Nasdaq: NRIX) ha nominato Anil Kapur nel suo consiglio di amministrazione, con effetto dal 15 ottobre 2024. Il signor Kapur porta oltre 25 anni di esperienza gestionale in aziende farmaceutiche e biotecnologiche nei mercati statunitensi e internazionali. La sua esperienza nelle operazioni commerciali e nel lancio di nuovi farmaci in ematologia e oncologia è particolarmente rilevante per il pipeline di Nurix.
Tra i risultati significativi del signor Kapur c'è il lancio di farmaci di successo come Imbruvica e Darzalex mentre era in Johnson & Johnson. Ha ricoperto posizioni di leadership in diverse aziende, tra cui Geron, Actinium Pharmaceuticals e Bristol-Myers Squibb. Nurix si sta preparando a portare NX-5948 in fase di test clinici decisivi nel 2025 e sta pianificando la commercializzazione futura.
Nurix Therapeutics (Nasdaq: NRIX) ha nombrado a Anil Kapur en su junta directiva, con efecto a partir del 15 de octubre de 2024. El Sr. Kapur aporta más de 25 años de experiencia ejecutiva en empresas farmacéuticas y biotecnológicas en los mercados de EE.UU. y internacionales. Su experiencia en operaciones comerciales y en el lanzamiento de nuevos medicamentos en hematología y oncología es especialmente relevante para la cartera de Nurix.
Entre los logros notables del Sr. Kapur se encuentra el lanzamiento de los medicamentos exitosos Imbruvica y Darzalex mientras estaba en Johnson & Johnson. Ha ocupado puestos de liderazgo en varias empresas, incluyendo Geron, Actinium Pharmaceuticals y Bristol-Myers Squibb. Nurix se está preparando para llevar NX-5948 a pruebas clínicas fundamentales en 2025 y está planificando la comercialización futura.
Nurix Therapeutics (Nasdaq: NRIX)는 Anil Kapur를 이사회에 임명했으며, 이는 2024년 10월 15일부터 효력이 발생합니다. Kapur 씨는 미국 및 국제 시장의 제약 및 생명공학 회사에서 25년 이상의 경영 경험을 보유하고 있습니다. 혈액학 및 종양학 분야의 새로운 의약품 출시와 상업 운영에 대한 그의 전문성은 Nurix의 파이프라인에 특히 관련이 있습니다.
Kapur 씨의 주요 성과 중 하나는 Johnson & Johnson에서 일할 때 성공적인 의약품인 Imbruvica와 Darzalex를 출시한 것입니다. 그는 Geron, Actinium Pharmaceuticals 및 Bristol-Myers Squibb를 포함한 여러 회사에서 고위 지도직을 역임했습니다. Nurix는 2025년에 NX-5948을 주요 임상 시험에 진입시키기 위해 준비 중이며, 향후 상업화를 계획하고 있습니다.
Nurix Therapeutics (Nasdaq: NRIX) a nommé Anil Kapur à son conseil d'administration, à compter du 15 octobre 2024. M. Kapur apporte plus de 25 ans d'expérience exécutive dans les entreprises pharmaceutiques et biopharmaceutiques sur les marchés américains et internationaux. Son expertise dans les opérations commerciales et le lancement de nouveaux médicaments en hématologie et en oncologie est particulièrement pertinente pour le portefeuille de Nurix.
Les réalisations notables de M. Kapur comprennent le lancement des médicaments à succès Imbruvica et Darzalex alors qu'il travaillait chez Johnson & Johnson. Il a occupé des postes de direction dans plusieurs entreprises, notamment Geron, Actinium Pharmaceuticals et Bristol-Myers Squibb. Nurix se prépare à faire avancer NX-5948 dans des essais cliniques décisifs en 2025 et prévoit une future commercialisation.
Nurix Therapeutics (Nasdaq: NRIX) hat Anil Kapur in seinen Vorstand berufen, wirksam ab dem 15. Oktober 2024. Herr Kapur bringt über 25 Jahre Erfahrung in Führungspositionen in pharmazeutischen und biotechnologischen Unternehmen sowohl auf dem US-amerikanischen als auch auf dem internationalen Markt mit. Seine Expertise in kommerziellen Operationen und der Einführung neuer Medikamente in der Hämatologie und Onkologie ist besonders relevant für das Pipeline von Nurix.
Zu den bemerkenswerten Erfolgen von Herrn Kapur gehört die Einführung der Blockbuster-Medikamente Imbruvica und Darzalex während seiner Zeit bei Johnson & Johnson. Er hat in verschiedenen Unternehmen, darunter Geron, Actinium Pharmaceuticals und Bristol-Myers Squibb, leitende Positionen innegehabt. Nurix bereitet sich darauf vor, NX-5948 im Jahr 2025 in entscheidende klinische Tests zu überführen und plant die zukünftige Kommerzialisierung.
- Appointment of Anil Kapur, an experienced pharmaceutical executive, to the board of directors
- Kapur's expertise in launching blockbuster drugs in hematology and oncology aligns with Nurix's pipeline
- Planned advancement of NX-5948 into pivotal clinical testing in 2025
- Preparation for future commercialization of drug candidates
- None.
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets.
“I am delighted to welcome Anil to the Nurix board as we enter this important stage in the company’s development and execute on our plan to advance NX-5948 into pivotal clinical testing in 2025 and prepare for future commercialization,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “Anil has an impressive record of commercial operations excellence and extensive experience launching novel drugs in hematology and oncology with direct relevance to Nurix’s pipeline, including the launch of blockbuster drugs Imbruvica and Darzalex while at Johnson & Johnson. I believe his strategic, marketing, sales and business development insights will be invaluable to Nurix in the years to come.”
Mr. Kapur began his pharmaceutical executive career as Vice President, Commercial Leader Hematology Franchise at Janssen Pharmaceuticals, Johnson & Johnson’s global pharmaceutical strategy organization. As the J&J Joint Commercialization Committee Leader in partnership with Pharmacyclics, Mr. Kapur launched Imbruvica, the first BTK inhibitor for chronic lymphocytic leukemia, achieving an estimated
“I am excited to join Nurix’s board of directors at this important time as NX-5948 is poised to enter pivotal trials and as we form the strategy for its commercialization,” said Mr. Kapur. “I believe Nurix’s targeted protein degrader drug pipeline has great potential to change the treatment landscape and help patients living with B cell malignancies and beyond.”
As a senior leader in hematology and oncology in both small and large organizations, Mr. Kapur has been responsible for launching significant global brands, building and managing commercial capabilities, driving corporate strategy and managing alliances. Most recently, Mr. Kapur served as Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation from December 2019 to August 2024. Prior to Geron, Mr. Kapur served as Chief Commercial Officer at Actinium Pharmaceuticals, Inc., and as Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb. Mr. Kapur is a member of the board of directors of Verastem, Inc., a late-stage development biopharmaceutical company. Mr. Kapur holds a BE in Mechanical Engineering from Birla Institute of Technology in India, an MS in Engineering from Louisiana Tech University, and an MBA from the Fuqua School of Business at Duke University.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the expected contributions Mr. Kapur will bring to Nurix, Nurix’s plans to advance NX-5948 into pivotal clinical testing in 2025, and the potential for Nurix’s targeted protein degrader drug pipeline to change the treatment landscape in B cell malignancies, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price. Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
Who is the new board member appointed to Nurix Therapeutics (NRIX)?
What is Nurix Therapeutics (NRIX) planning for NX-5948 in 2025?
What notable drugs did Anil Kapur help launch during his career?
What is Nurix Therapeutics (NRIX) focused on developing?
